BlueGnome Licenses Karyomapping IP in Bid to Bolster Pre-Implantation Genetic-Dx Play
October 19, 2010
BlueGnome Licenses Karyomapping IP in Bid to Bolster Pre-Implantation Genetic-Dx Play
Cambridge, UK-based BlueGnome made the acquisition to carve out a bigger piece of the pre-implantation, genetic-diagnostic market. The firm "aims to address diagnosis of single-gene disorders using SNP-array technology," according to its CEO.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BlueGnome Spinout Sure Laboratories Aims to Serve Growing IVF Screening Market
September 7, 2010 / BioArray News - Illumina's Q4 Array Revenues Climb 4 Percent on BlueGnome Addition, HumanCore Demand
January 29, 2013 / BioArray News - Study Backs BlueGnome CGH Arrays as Screening Tool to Improve IVF Success Rates
May 8, 2012 / BioArray News - At Investor Confab, Illumina CFO Discusses Sequestration, Japanese Market, BlueGnome
March 12, 2013 / BioArray News - Illumina Predicts Flat Future for Array Business as GWAS Decline Counters Growth in New Markets
October 30, 2012 / BioArray News